InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,352.96
(
-0.02%
)
US TECH 100
18,560.80
(
0.14%
)
Dow Jones
38,886.17
(
0.20%
)
Brent Oil
79.64
(
-0.31%
)
Bitcoin
71,123.13
(
0.51%
)
Post# of 17432
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

moosedogger

Send PM Follow Ignore
Followers 6
Posts 1087
Boards Moderated 0
Alias Born 07/18/2006

moosedogger

Re: Jesspro post# 7944

Tuesday, 01/29/2019 8:28:14 AM

Tuesday, January 29, 2019 8:28:14 AM

Post# of 17432
The case for AGN buying VOS appears to be substantial.

Allergan certainly realizes that VOS is superior to Restasis and will be approved eventually (and likely could be approved faster with AGN's help).

AGN's #1 and #2 franchises are Botox and Restasis, and both are threatened (by RVNC and AUPH, among others).

Buying VOS now would be a win-win for both AGN and AUPH as Aurinia could focus solely on LN and FSGS and not be distracted with DES which is not really their bailiwick.

A VOS buyout would allow AGN to continue to dominate the growing DES market.

Here's hoping AGN or MRK or another BP make it happen fairly soon.



Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AUPH News
More AUPH News
InvestorsHub NewsWire

Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM

Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM

Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM

Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM

IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM

ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM

Start posting your company's news
Only $200 per official company press release!